Molecular Modelling, Molecular Docking, Molecular Dynamic Simulations, MM-GBSA Study, and Pharmacokinetics Prediction of New Isatin-Sulfonamide Derivatives as Selective Carbonic Anhydrase CA IX Inhibitors
DOI:
https://doi.org/10.32947/ajps.v26i3.1371Keywords:
Molecular Docking, Molecular Dynamic Simulations, MM-GBSA Study, Isatin-Sulfonamide, Carbonic Anhydrase CA IXAbstract
Hypoxia within solid tumors triggers upregulation of carbonic anhydrase IX (CA IX), a key enzyme that maintains pH homeostasis and supports tumor survival, invasion, and therapy resistance. Selective CA IX inhibition is considered a promising anticancer strategy, but current inhibitors often lack isoform selectivity. This study aimed to synthesize a selective and potent CA IX inhibitor by designing a novel series of isatin-sulfonamide hybrid compounds. Five hybrid molecules were computationally assessed via molecular docking, General Born Surface Area (MM-GBSA) free energy calculations, and molecular dynamics simulations. Results identified Compound 3 as the most promising candidate, revealing strong binding affinity (docking score: –6.299 kcal/mol), a favorable free energy of binding (–28.24 kcal/mol), and stable interactions within the CA IX active site. Moreover, these hybrids exhibited enhanced toxicity profiles compared to the native ligand, with lower potential carcinogenicity and higher LD₅₀ values. The study concludes that isatin-sulfonamide hybrids, especially Compound 3, provide a Synergistic strategy for selectively disturbing hypoxic tumor metabolism, necessitating further experimental evaluation for development as anticancer agents.
References
1. Bader SB, Dewhirst MW, Hammond EM. Cyclic hypoxia: an update on its characteristics, methods to measure it and biological implications in cancer. Cancers (Basel). 2020;13(1):23.
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev [Internet]. 2007;26(2):225–39. Available from: https://doi.org/10.1007/s10555-007-9055-1
3. de Heer EC, Jalving M, Harris AL. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest. 2020;130(10):5074–87.
4. Harris AL. Hypoxia — a key regulatory factor in tumour growth. Nat Rev Cancer [Internet]. 2002;2(1):38–47. Available from: https://doi.org/10.1038/nrc704
5. Semenza GL. HIF-1: Using Two Hands to Flip the Angiogenic Switch. Cancer Metastasis Rev [Internet]. 2000;19(1):59–65. Available from: https://doi.org/10.1023/A:1026544214667
6. Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, et al. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat. 2021;59:100787.
7. Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Semin Cancer Biol [Internet]. 2014;1–13. Available from: http://dx.doi.org/10.1016/j.semcancer.2014.08.002
8. Swietach P, Hulikova A, Vaughan-jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene [Internet]. 2010;29(50):6509–21. Available from: http://dx.doi.org/10.1038/onc.2010.455
9. Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat [Internet]. 2018 Oct 3;28(10):709–12. Available from: https://doi.org/10.1080/13543776.2018.1523897
10. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov [Internet]. 2008;7(2):168–81. Available from: https://doi.org/10.1038/nrd2467
11. Alterio V, Di Fiore A, D’Ambrosio K, Supuran CT, De Simone G. Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms? Chem Rev [Internet]. 2012 Aug 8;112(8):4421–68. Available from: https://doi.org/10.1021/cr200176r
12. Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2021;30(12):1197–208.
13. Singh GS, Desta ZY. Isatins As Privileged Molecules in Design and Synthesis of Spiro-Fused Cyclic Frameworks. Chem Rev [Internet]. 2012 Nov 14;112(11):6104–55. Available from: https://doi.org/10.1021/cr300135y
14. Krasavin M, Kalinin S, Sharonova T, Supuran CT. Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents. J Enzyme Inhib Med Chem [Internet]. 2020 Jan 1;35(1):1555–61. Available from: https://doi.org/10.1080/14756366.2020.1801674
15. Angeli A, Carta F, Nocentini A, Winum JY, Zalubovskis R, Akdemir A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10(10):1–21.
16. Shaldam MA, Almahli H, Angeli A, Badi RM, Khaleel EF, Zain-Alabdeen AI, et al. Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors. J Enzyme Inhib Med Chem [Internet]. 2023;38(1). Available from: https://doi.org/10.1080/14756366.2023.2203389
17. Sastry GM, Adzhigirey M, Sherman W. Protein and ligand preparation : parameters , protocols , and influence on virtual screening enrichments. 2013;221–34.
18. Jorgensen WL, Tirado-Rives J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc [Internet]. 1988 Mar 1;110(6):1657–66. Available from: https://doi.org/10.1021/ja00214a001
19. Ibrahim ZN, Khan AK, Hamdi MD, Awad A. Drug Design , In Silico-Profiling of New Pyrrole Derivatives : Promising Anticancer Agents Against Acute Myeloid Leukemia. Al Mustansiriyah J Pharm Sci. 2024;24(3):252–65.
20. Fadhil SA, Ali KF, Mehde WA. In-Silico Evaluation of Binding Interaction and ADME Properties of Novel Pyrazoline and Pyrimidine Derivatives Targeting Cyclooxygenase-2 Enzyme . ). Al Mustansiriyah J Pharm Sci. 2025;25(1):110–30.
21. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep [Internet]. 2017;7(1):42717. Available from: https://doi.org/10.1038/srep42717
22. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J Med Chem [Internet]. 2002 Jun 1;45(12):2615–23. Available from: https://doi.org/10.1021/jm020017n
23. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J Med Chem [Internet]. 2004 Mar 1;47(7):1739–49. Available from: https://doi.org/10.1021/jm0306430
24. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects. J Med Chem [Internet]. 2006 Jan 1;49(2):534–53. Available from: https://doi.org/10.1021/jm050540c
25. Jacobson MP, Pincus DL, Rapp CS, Day TJF, Honig B, Shaw DE, et al. A Hierarchical Approach to All-Atom Protein Loop Prediction. 2004;367(April 2003):351–67.
26. Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. J Chem Theory Comput [Internet]. 2016 Jan 12;12(1):281–96. Available from: https://doi.org/10.1021/acs.jctc.5b00864
27. Li J, Abel R, Zhu K, Cao Y, Zhao S, Friesner RA. The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. 2011;2794–812.
28. Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, et al. End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. Chem Rev [Internet]. 2019 Aug 28;119(16):9478–508. Available from: https://doi.org/10.1021/acs.chemrev.9b00055
29. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, Jorgensen WL, et al. Comparison of simple potential functions for simulating liquid water Comparison of simple potential functions for simulating liquid water. 1983;926(May 2012).
30. Flori L, Brogi S, Sirous H, Calderone V. Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes. Int J Mol Sci [Internet]. 2023;24(8). Available from: https://www.mdpi.com/1422-0067/24/8/7578
31. Roos K, Wu C, Damm W, Reboul M, Stevenson JM, Lu C, et al. OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules. J Chem Theory Comput [Internet]. 2019 Mar 12;15(3):1863–74. Available from: https://doi.org/10.1021/acs.jctc.8b01026
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mustafa hussein ali, Monther Faisal Mahdi
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
